Ligand Pharmaceuticals (LGND) Cash from Financing Activities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Cash from Financing Activities data on file, last reported at -$14.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 197.72% year-over-year to -$14.1 million; the trailing twelve-month figure through Mar 2026 stood at $418.8 million (up 422.16% YoY), and the FY2025 full-year result was $428.2 million, up 340.83% from the prior year.
• Cash from Financing Activities eased to -$14.1 million in Q1 2026, from $8.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $409.6 million in Q3 2025 to a low of -$170.4 million in Q1 2022.
• A 5-year average of $10.3 million and a median of $3.3 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 10504.94% in 2022 and jumped 1671.87% in 2024, its largest moves.
• Tracing LGND's Cash from Financing Activities over 5 years: stood at -$5.3 million in 2022, then jumped by 200.32% to $5.3 million in 2023, then soared by 283.59% to $20.4 million in 2024, then slumped by 59.14% to $8.3 million in 2025, then slumped by 269.66% to -$14.1 million in 2026.
• Business Quant data shows LGND's Cash from Financing Activities at -$14.1 million in Q1 2026, $8.3 million in Q4 2025, and $409.6 million in Q3 2025.